

Anthony S Wierzbicki

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8500777/publications.pdf>

Version: 2024-02-01

383
papers

9,841
citations

43973

48
h-index

56606

83
g-index

392
all docs

392
docs citations

392
times ranked

10497
citing authors

#	ARTICLE	IF	CITATIONS
1	Options for the diagnosis of high blood pressure in primary care: a systematic review and economic model. <i>Journal of Human Hypertension</i> , 2021, 35, 455-461.	1.0	12
2	Identification of patients with Fabry disease using routine pathology results: PATHFINDER (eGFR) study. <i>International Journal of Clinical Practice</i> , 2021, 75, e13672.	0.8	4
3	Cost-Effectiveness of Initiating Pharmacological Treatment in Stage One Hypertension Based on 10-Year Cardiovascular Disease Risk. <i>Hypertension</i> , 2021, 77, 682-691.	1.3	12
4	Triglycerides and cardiovascular disease. <i>Current Opinion in Cardiology</i> , 2021, 36, 469-477.	0.8	19
5	Impact of Therapeutic Inertia on Long-Term Blood Pressure Control. <i>Hypertension</i> , 2021, 77, 1350-1359.	1.3	10
6	Screening for patients with Gaucher's disease using routine pathology results: PATHFINDER (ferritin,) Tj ETQq0 0 0 ggBT /Overlock 10 Tf	0.8	2
7	Investigating raised creatine kinase. <i>BMJ, The</i> , 2021, 373, n1486.	3.0	3
8	Elevated Lipoprotein(a): Background, Current Insights and Future Potential Therapies. <i>Vascular Health and Risk Management</i> , 2021, Volume 17, 527-542.	1.0	15
9	<p>Volanesorsen in the Treatment of Familial Chylomicronemia Syndrome or Hypertriglyceridaemia: Design, Development and Place in Therapy<p>. <i>Drug Design, Development and Therapy</i> , 2020, Volume 14, 2623-2636.	2.0	45
10	Phenomics, Not Genomics, for Cardiovascular Risk Assessment. <i>Circulation</i> , 2020, 142, 821-823.	1.6	1
11	Reorganizing the treatment of cardiovascular disease in response to coronavirus disease 2019; time for the polypill?. <i>Current Opinion in Cardiology</i> , 2020, 35, 428-433.	0.8	7
12	Ten tips for promoting your research. <i>Cardiovascular Endocrinology and Metabolism</i> , 2020, 9, 30-35.	0.5	3
13	Managing cardiovascular disease risk in hypertension. <i>Lancet, The</i> , 2020, 395, 869-870.	6.3	5
14	Low cholesterol syndrome and drug development. <i>Current Opinion in Cardiology</i> , 2020, 35, 423-427.	0.8	1
15	The history of proprotein convertase subtilisin kexin-9 inhibitors and their role in the treatment of cardiovascular disease. <i>Therapeutic Advances in Chronic Disease</i> , 2020, 11, 204062232092456.	1.1	8
16	SPRINT: Running into trouble?. <i>International Journal of Clinical Practice</i> , 2020, 74, e13468.	0.8	0
17	Cardiovascular prevention: Frontiers in lipid guidelines. <i>Clinical Medicine</i> , 2020, 20, 36-42.	0.8	6
18	Hypertension in adults: summary of updated NICE guidance. <i>BMJ: British Medical Journal</i> , 2019, 367, l5310.	2.4	57

#	ARTICLE	IF	CITATIONS
19	Computational models and neural nets: Fantastic modelsâ€”Where to find them and how to identify them. <i>International Journal of Clinical Practice</i> , 2019, 73, e13391.	0.8	1
20	Primum non nocere: Demand management in pathology and preventing harm. <i>International Journal of Clinical Practice</i> , 2019, 73, e13311.	0.8	1
21	Treating lipids in secondary prevention in a developing country: Lies, damn lies and the internet. <i>International Journal of Clinical Practice</i> , 2019, 73, 1-3.	0.8	0
22	An audit of research productivity in clinical biochemistry revisited. <i>JRSM Open</i> , 2019, 10, 205427041984418.	0.2	0
23	Noncoronary Artery Disease in Familial Hypercholesterolemia: Underdiagnosis of Peripheral Arterial Disease?. <i>Angiology</i> , 2019, 70, 893-895.	0.8	1
24	Genetic risk scores in lipid disorders. <i>Current Opinion in Cardiology</i> , 2019, 34, 406-412.	0.8	7
25	Identification of patients with Pompe disease using routine pathology results: PATHFINDER (creatinine) Tj ETQq1 1.0,784314 rgBT /Ove	1.0	2
26	Demand management of weekend haematology and clinical biochemistry requests. <i>International Journal of Clinical Practice</i> , 2019, 73, e13297.	0.8	4
27	Bile acid metabolism is altered in those with insulin resistance after gestational diabetes mellitus. <i>Clinical Biochemistry</i> , 2019, 64, 12-17.	0.8	13
28	Identification of rare diseases by screening a population selected on the basis of routine pathology resultsâ€”the PATHFINDER project: lysosomal acid lipase/cholesteryl ester storage disease substudy. <i>Journal of Clinical Pathology</i> , 2018, 71, 608-613.	1.0	11
29	Is Lp(a) ready for prime time use in the clinic? A pros-and-cons debate. <i>Atherosclerosis</i> , 2018, 274, 16-22.	0.4	30
30	An update on trials of novel lipid-lowering drugs. <i>Current Opinion in Cardiology</i> , 2018, 33, 416-422.	0.8	5
31	Suboptimal rise in awakening-induced cortisol is an accurate marker of cortisol insufficiency in patients with normal renal function (eGFR >60â€”mL/min). <i>Annals of Clinical Biochemistry</i> , 2018, 55, 496-499.	0.8	0
32	Chronic heart failure in adults: summary of updated NICE guidance. <i>BMJ: British Medical Journal</i> , 2018, 362, k3646.	2.4	23
33	Review of referral criteria to lipid clinics and outcomes of treatment in 4 UK centres. <i>Atherosclerosis</i> , 2018, 275, e239.	0.4	0
34	Pro-protein subtilisin kexin-9 (PCSK9) inhibition in practice: Lipid clinic experience in 2 contrasting UK centres. <i>Atherosclerosis</i> , 2018, 275, e100.	0.4	0
35	Review of referral criteria to lipid clinics and outcomes of treatment in four UK centres. <i>International Journal of Clinical Practice</i> , 2018, 72, e13242.	0.8	2
36	Further options for treating lipids in people with diabetes: targeting <sc>LDL</sc>â€”cholesterol and beyond. <i>Diabetic Medicine</i> , 2018, 35, 1173-1180.	1.2	3

#	ARTICLE	IF	CITATIONS
37	Pharmacological treatment options for severe hypertriglyceridemia and familial chylomicronemia syndrome. <i>Expert Review of Clinical Pharmacology</i> , 2018, 11, 589-598.	1.3	34
38	Radiotherapy, chemotherapy and atherosclerosis. <i>Current Opinion in Cardiology</i> , 2017, 32, 441-447.	0.8	28
39	Sensible economies: Demand management in blood science laboratories. <i>International Journal of Clinical Practice</i> , 2017, 71, e12942.	0.8	2
40	Evolocumab for Treating Primary Hypercholesterolaemia and Mixed Dyslipidaemia: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. <i>Pharmacoeconomics</i> , 2017, 35, 537-547.	1.7	18
41	The challenges of proprotein convertase subtilisin kexin-9 inhibitors for lipid guidelines and models of care. <i>Current Opinion in Lipidology</i> , 2017, 28, 470-476.	1.2	1
42	Pro-protein subtilisin kexin-9 (PCSK9) inhibition in practice: lipid clinic experience in 2 contrasting UK centres. <i>International Journal of Clinical Practice</i> , 2017, 71, e13032.	0.8	33
43	Familial hypercholesterolaemia. <i>Nature Reviews Disease Primers</i> , 2017, 3, 17093.	18.1	315
44	Assessment of a semi-quantitative screening method for diagnosis of ethylene glycol poisoning. <i>Annals of Clinical Biochemistry</i> , 2017, 54, 501-503.	0.8	2
45	Statins, Muscle Disease and Mitochondria. <i>Journal of Clinical Medicine</i> , 2017, 6, 75.	1.0	61
46	The impact of lipoprotein lipase deficiency on health-related quality of life: a detailed, structured, qualitative study. <i>Orphanet Journal of Rare Diseases</i> , 2017, 12, 156.	1.2	12
47	Statin myopathy. <i>Current Opinion in Cardiology</i> , 2016, 31, 417-425.	0.8	7
48	Moving the goalposts - towards cardiovascular prevention. <i>International Journal of Clinical Practice</i> , 2016, 70, 429-431.	0.8	0
49	Drugs for hypercholesterolaemia - from statins to pro-protein convertase subtilisin kexin 9 (PCSK9) inhibition. <i>Clinical Medicine</i> , 2016, 16, 353-357.	0.8	8
50	The Challenges of a Successful Pregnancy in a Patient with Adult Refsum's Disease due to Phytanoyl-CoA Hydroxylase Deficiency. <i>JIMD Reports</i> , 2016, 33, 49-53.	0.7	6
51	Evolocumab for Treating Primary Hypercholesterolaemia and Mixed Dyslipidaemia: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. <i>Pharmacoeconomics</i> , 2016, 35, 537.	1.7	4
52	Mind the gap - surviving in the modern world. <i>International Journal of Clinical Practice</i> , 2016, 70, 517-519.	0.8	0
53	Anti-sense oligonucleotide therapies for the treatment of hyperlipidaemia. <i>Expert Opinion on Biological Therapy</i> , 2016, 16, 1125-1134.	1.4	23
54	Safety of long-term restrictive diets for peroxisomal disorders: vitamin and trace element status of patients treated for Adult Refsum Disease. <i>International Journal of Clinical Practice</i> , 2016, 70, 229-235.	0.8	7

#	ARTICLE	IF	CITATIONS
55	Nonfasting Sample for the Determination of Routine Lipid Profile: Is It an Idea Whose Time Has Come?. <i>Clinical Chemistry</i> , 2016, 62, 428-435.	1.5	22
56	Familial Hypercholesterolaemia in the Era of Genetic Testing. <i>Current Cardiology Reports</i> , 2016, 18, 42.	1.3	6
57	Erectile dysfunction and coronary heart disease. <i>Current Opinion in Cardiology</i> , 2015, 30, 416-421.	0.8	35
58	Improving the odds: ezetimibe and cardiovascular disease. <i>International Journal of Clinical Practice</i> , 2015, 69, 390-395.	0.8	2
59	Bariatric surgery in obese older people. <i>Cardiovascular Endocrinology</i> , 2015, 4, 60-66.	0.8	3
60	Pro-protein convertase subtilisin/kexin 9 concentrations correlate with coronary artery disease atheroma burden in a Pakistani cohort with chronic chest pain. <i>International Journal of Clinical Practice</i> , 2015, 69, 738-742.	0.8	10
61	The hinterland of familial hypercholesterolaemia. <i>Current Opinion in Lipidology</i> , 2015, 26, 475-483.	1.2	6
62	Prioritizing health outcomes in a limited world. <i>Current Opinion in Lipidology</i> , 2015, 26, 188-194.	1.2	2
63	Integrated guidance on the care of familial hypercholesterolaemia from the International FH Foundation. <i>European Journal of Preventive Cardiology</i> , 2015, 22, 849-854.	0.8	60
64	The Agenda for Familial Hypercholesterolemia. <i>Circulation</i> , 2015, 132, 2167-2192.	1.6	539
65	Evaluating quality and its determinants in lipid control for secondary prevention of heart disease and stroke in primary care: a study in an inner London Borough. <i>BMJ Open</i> , 2015, 5, e008678.	0.8	5
66	Vitamin K and other markers of micronutrient status in morbidly obese patients before bariatric surgery. <i>International Journal of Clinical Practice</i> , 2015, 69, 638-642.	0.8	19
67	Clinical management of familial hypercholesterolemia: new insights from international guidelines and recent studies. <i>Neurology International</i> , 2014, 4, .	0.2	0
68	Interrupting the Natural History of Diabetes Mellitus: Lifestyle, Pharmacological and Surgical Strategies Targeting Disease Progression. <i>Current Vascular Pharmacology</i> , 2014, 12, 155-167.	0.8	7
69	Fibrates and niacin: is there a place for them in clinical practice?. <i>Expert Opinion on Pharmacotherapy</i> , 2014, 15, 2673-2680.	0.9	11
70	Dyslipidaemia: what's around the corner?. <i>Clinical Medicine</i> , 2014, 14, s41-s44.	0.8	5
71	Statin-fibrate combination therapy is safe and effective in normalizing lipid profile and in keeping cardiovascular event rates low. <i>Current Medical Research and Opinion</i> , 2014, 30, 57-58.	0.9	3
72	Lipid-lowering drug therapies and chronic obstructive pulmonary disease: lung failure or just heart failure?. <i>International Journal of Clinical Practice</i> , 2014, 68, 144-151.	0.8	1

#	ARTICLE	IF	CITATIONS
73	Should we expand the concept of coronary heart disease equivalents?. <i>Current Opinion in Cardiology</i> , 2014, 29, 389-395.	0.8	47
74	Integrated guidance on the care of familial hypercholesterolemia from the International FH Foundation. <i>Journal of Clinical Lipidology</i> , 2014, 8, 148-172.	0.6	98
75	Lipid modification and cardiovascular risk assessment for the primary and secondary prevention of cardiovascular disease: summary of updated NICE guidance. <i>BMJ</i> , The, 2014, 349, g4356-g4356.	3.0	236
76	The Ebbs and Flows in the Development of Cholesterol-Lowering Drugs: Prospects for the Future. <i>Clinical Pharmacology and Therapeutics</i> , 2014, 96, 64-73.	2.3	13
77	Integrated guidance on the care of familial hypercholesterolaemia from the International FH Foundation. <i>International Journal of Cardiology</i> , 2014, 171, 309-325.	0.8	316
78	Angiographic coronary artery disease and high-sensitivity troponin-T in a native Pakistani cohort presenting with chronic chest pain. <i>International Journal of Clinical Practice</i> , 2014, 68, 1473-1477.	0.8	0
79	Dyslipidaemia Related to Insulin Resistance and Cardiovascular Disease in South Asian and West African Populations. <i>Current Pharmaceutical Design</i> , 2014, 20, 6270-6275.	0.9	8
80	All at sea: new lipid-lowering drug trials continue to disappoint. <i>International Journal of Clinical Practice</i> , 2013, 67, 595-598.	0.8	3
81	Lipid-Lowering Agents. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2013, 18, 401-411.	1.0	28
82	Secondary tests for stratification of risk for atherosclerosis. <i>Current Medical Research and Opinion</i> , 2013, 29, 597-599.	0.9	0
83	U.K. consensus statement on safe clinical prescribing of bexarotene for patients with cutaneous T-cell lymphoma. <i>British Journal of Dermatology</i> , 2013, 168, 192-200.	1.4	81
84	Screening for chronic comorbid diseases in people with <sc>HIV</sc>: the need for a strategic approach. <i>HIV Medicine</i> , 2013, 14, 1-11.	1.0	27
85	Failure to THRIVE: the end for niacin?. <i>Nature Reviews Cardiology</i> , 2013, 10, 246-247.	6.1	3
86	The Need for Combination Drug Therapies in Patients with Complex Dyslipidemia. <i>Current Cardiology Reports</i> , 2013, 15, 391.	1.3	9
87	Alipogene tiparvovec: gene therapy for lipoprotein lipase deficiency. <i>Expert Opinion on Biological Therapy</i> , 2013, 13, 7-10.	1.4	39
88	Effectiveness of alternative strategies to define index case phenotypes to aid genetic diagnosis of familial hypercholesterolaemia. <i>Heart</i> , 2013, 99, 175-180.	1.2	39
89	Epicardial fat and vascular risk. <i>Current Opinion in Cardiology</i> , 2013, 28, 458-463.	0.8	70
90	CDKN2B expression in adipose tissue of familial combined hyperlipidemia patients. <i>Journal of Lipid Research</i> , 2013, 54, 3491-3505.	2.0	23

#	ARTICLE	IF	CITATIONS
91	New therapies to reduce low-density lipoprotein cholesterol. <i>Current Opinion in Cardiology</i> , 2013, 28, 452-457.	0.8	22
92	Sugar, sugar. <i>International Journal of Clinical Practice</i> , 2013, 67, 294-296.	0.8	1
93	Doubling up: maximising statin therapy as opposed to adding other drugs for cardiovascular disease prevention. <i>International Journal of Clinical Practice</i> , 2013, 67, 391-393.	0.8	0
94	Lower, faster, better: the delusions of surrogate markers in hypertension. <i>International Journal of Clinical Practice</i> , 2013, 67, 822-824.	0.8	0
95	Homozygous familial hypercholesterolemia. <i>Clinical Lipidology</i> , 2013, 8, 407-409.	0.4	1
96	A Cross-Sectional Randomised Study of Fracture Risk in People with HIV Infection in the Probono 1 Study. <i>PLoS ONE</i> , 2013, 8, e78048.	1.1	24
97	Triglycerides. <i>Current Opinion in Cardiology</i> , 2012, 27, 398-404.	0.8	32
98	Statins and noncardiac vascular disease. <i>Current Opinion in Cardiology</i> , 2012, 27, 392-397.	0.8	22
99	The fats of life in diabetes. <i>British Journal of Diabetes and Vascular Disease</i> , 2012, 12, 216-220.	0.6	3
100	Diagnosis and treatment of severe hypertriglyceridemia. <i>Expert Review of Cardiovascular Therapy</i> , 2012, 10, 505-514.	0.6	30
101	Prescribing high-dose lipid-lowering therapy early to avoid subsequent cardiovascular events: is this a cost-effective strategy?. <i>European Journal of Preventive Cardiology</i> , 2012, 19, 474-483.	0.8	18
102	Nonalcoholic fatty liver disease and lipids. <i>Current Opinion in Lipidology</i> , 2012, 23, 345-352.	1.2	49
103	Daily and intermittent rosuvastatin 5â€‰mg therapy in statin intolerant patients: an observational study. <i>Current Medical Research and Opinion</i> , 2012, 28, 371-378.	0.9	45
104	Inhibition of pre-protein convertase serine kexin-9 (PCSK-9) as a treatment for hyperlipidaemia. <i>Expert Opinion on Investigational Drugs</i> , 2012, 21, 667-676.	1.9	36
105	The origin, global distribution, and functional impact of the human 8p23 inversion polymorphism. <i>Genome Research</i> , 2012, 22, 1144-1153.	2.4	70
106	New lipid-lowering drugs: an update. <i>International Journal of Clinical Practice</i> , 2012, 66, 270-280.	0.8	61
107	The Effect of a 12-Week Course of Omega-3 Polyunsaturated Fatty Acids on Lipid Parameters in Hypertriglyceridemic Adult HIV-infected Patients Undergoing HAART: A Randomized, Placebo-Controlled Pilot Trial. <i>Clinical Therapeutics</i> , 2012, 34, 67-76.	1.1	28
108	Lumping and splitting in cardiovascular risk. <i>International Journal of Clinical Practice</i> , 2012, 66, 522-524.	0.8	2

#	ARTICLE	IF	CITATIONS
109	New directions in cardiovascular risk assessment: the role of secondary risk stratification markers. International Journal of Clinical Practice, 2012, 66, 622-630.	0.8	22
110	The assessment of metabolic syndrome in UK patients with HIV using two different definitions: CREATE 2 study. Current Medical Research and Opinion, 2011, 27, 63-69.	0.9	18
111	Association of bone turnover markers and arterial stiffness in pre-dialysis chronic kidney disease (CKD). Bone, 2011, 48, 1127-1132.	1.4	40
112	Ideal lipid profile and genes for an extended life span. Current Opinion in Cardiology, 2011, 26, 348-355.	0.8	12
113	Pulmonary arterial hypertension and statins: an update. Current Opinion in Cardiology, 2011, 26, 322-326.	0.8	18
114	“European Panel On Low Density Lipoprotein (LDL) Subclasses”: A Statement on the Pathophysiology, Atherogenicity and Clinical Significance of LDL Subclasses: Executive Summary. Current Vascular Pharmacology, 2011, 9, 531-532.	0.8	110
115	Gender-based cardiometabolic risk evaluation in minority and non-minority men grading the evidence of non-traditional determinants of cardiovascular risk. International Journal of Clinical Practice, 2011, 65, 134-147.	0.8	11
116	Cardiovascular screening: which populations, what measures of risk?. International Journal of Clinical Practice, 2011, 65, 3-5.	0.8	0
117	Statin wars: efficacy vs. cost. International Journal of Clinical Practice, 2011, 65, 108-111.	0.8	0
118	Niacin: the only vitamin that reduces cardiovascular events. International Journal of Clinical Practice, 2011, 65, 379-385.	0.8	27
119	Rimonabant improves cholesterol, insulin resistance and markers of non-alcoholic fatty liver in morbidly obese patients: a retrospective cohort study. International Journal of Clinical Practice, 2011, 65, 713-715.	0.8	12
120	A renaissance for cardio-metabolic surgery: better outcomes and lower costs?. International Journal of Clinical Practice, 2011, 65, 728-732.	0.8	3
121	HDL: who needs it?. International Journal of Clinical Practice, 2011, 65, 1111-1113.	0.8	4
122	The ezetimibe Jonah: the trials and tribulations of an unlucky drug. International Journal of Clinical Practice, 2011, 65, 1207-1208.	0.8	22
123	NO Problem: Arterial and Venous Endothelial Function and Erectile Dysfunction. European Urology, 2011, 59, 956-958.	0.9	3
124	Cardiovascular disease and the seeds of innovation: a call for papers. International Journal of Clinical Practice, 2011, 65, 107-108.	0.8	2
125	The incidence of low eGFR and proteinuria in a large tertiary referral lipid clinic. International Urology and Nephrology, 2011, 43, 821-825.	0.6	1
126	New Lipid Modulating Drugs: The Role of Microsomal Transport Protein Inhibitors. Current Pharmaceutical Design, 2011, 17, 943-949.	0.9	29

#	ARTICLE	IF	CITATIONS
127	“European Panel on Low Density Lipoprotein (LDL) Subclasses”: A Statement on the Pathophysiology, Atherogenicity and Clinical Significance of LDL Subclasses. <i>Current Vascular Pharmacology</i> , 2011, 9, 533-571.	0.8	187
128	Investigating mixed hyperlipidaemia. <i>BMJ: British Medical Journal</i> , 2011, 343, d5146-d5146.	2.4	2
129	Sodium-Glucose Co-Transporter 2 Inhibitors: From Apple Tree to ‘Sweet Pee’. <i>Current Pharmaceutical Design</i> , 2010, 16, 3830-3838.	0.9	15
130	Aortic stenosis and lipids: does intervention work?. <i>Current Opinion in Cardiology</i> , 2010, 25, 379-384.	0.8	16
131	Fibrates: no ACCORD on their use in the treatment of dyslipidaemia. <i>Current Opinion in Lipidology</i> , 2010, 21, 352-358.	1.2	34
132	Aggressive statin treatment, very low serum cholesterol levels and haemorrhagic stroke: is there an association?. <i>Current Opinion in Cardiology</i> , 2010, 25, 406-410.	0.8	23
133	Colesevelam: an improved bile acid sequestrant for treating hypercholesterolemia and improving diabetes. <i>Expert Review of Endocrinology and Metabolism</i> , 2010, 5, 825-834.	1.2	2
134	Fibroblast growth factor-23 is associated with C-reactive protein, serum phosphate and bone mineral density in chronic kidney disease. <i>Osteoporosis International</i> , 2010, 21, 1853-1861.	1.3	76
135	Putting protection first: vascular risk assessment in atypical populations. <i>International Journal of Clinical Practice</i> , 2010, 64, 664-666.	0.8	2
136	Cardiovascular risk evaluation and antiretroviral therapy effects in an HIV cohort: implications for clinical management: the CREATE 1 study. <i>International Journal of Clinical Practice</i> , 2010, 64, 1252-1259.	0.8	45
137	Practice makes perfect: reflections on a primary care treatment-to-target study. <i>International Journal of Clinical Practice</i> , 2010, 64, 1006-1008.	0.8	4
138	Comparing apples and pears: assessment of lipid-lowering therapies differentiated by side effects. <i>International Journal of Clinical Practice</i> , 2010, 64, 1324-1326.	0.8	0
139	The Poly-pill: does it work and is chronic therapy acceptable?. <i>International Journal of Clinical Practice</i> , 2010, 64, 1171-1173.	0.8	3
140	Safety and efficacy of laropiprant and extended-release niacin combination in the management of mixed dyslipidemias and primary hypercholesterolemia. <i>Drug, Healthcare and Patient Safety</i> , 2010, 2, 61.	1.0	4
141	The effectiveness of long-term dietary therapy in the treatment of adult Refsum disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2010, 81, 954-957.	0.9	71
142	The effect of fibrate—statin combination therapy on cardiovascular events: a retrospective cohort analysis. <i>Current Medical Research and Opinion</i> , 2010, 26, 2141-2146.	0.9	13
143	Hyperlipidaemia in Paediatric Patients. <i>Drug Safety</i> , 2010, 33, 115-125.	1.4	18
144	Adult Refsum Disease: A Form of Tapetoretinal Dystrophy Accessible to Therapy. <i>Survey of Ophthalmology</i> , 2010, 55, 531-538.	1.7	35

#	ARTICLE	IF	CITATIONS
145	Getting better value from the NHS drug budget. <i>BMJ: British Medical Journal</i> , 2010, 341, c6449-c6449.	2.4	25
146	The copper/caeruloplasmin ratio in routine clinical practice in different laboratories. <i>Journal of Clinical Pathology</i> , 2009, 62, 60-63.	1.0	14
147	Targeting triglycerides in secondary prevention: should we bother?. <i>International Journal of Clinical Practice</i> , 2009, 63, 15-18.	0.8	3
148	SEARCHing for JUPITER: starry-eyed optimism is not warranted. <i>International Journal of Clinical Practice</i> , 2009, 63, 685-688.	0.8	5
149	Truthiness and quality improvement. <i>International Journal of Clinical Practice</i> , 2009, 63, 839-840.	0.8	0
150	Vascular risk screening: possible or too much, too soon?. <i>International Journal of Clinical Practice</i> , 2009, 63, 989-996.	0.8	6
151	Storms, tea cups and the adverse effects of statins. <i>International Journal of Clinical Practice</i> , 2009, 63, 1268-1270.	0.8	4
152	Hot and bothered: C-reactive protein, inflammation and atherosclerosis. <i>International Journal of Clinical Practice</i> , 2009, 63, 1550-1553.	0.8	5
153	Interpreting clinical trials of diabetic dyslipidaemia: new insights. <i>Diabetes, Obesity and Metabolism</i> , 2009, 11, 261-270.	2.2	8
154	Factors regulating circulating vascular endothelial growth factor (VEGF): Association with bone mineral density (BMD) in post-menopausal osteoporosis. <i>Cytokine</i> , 2009, 46, 376-381.	1.4	31
155	Are intensive lipid-lowering regimens an optimal economic strategy in patients with ACS? An acute and chronic perspective. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2009, 9, 423-433.	0.7	4
156	Lipoprotein a: where are we now?. <i>Current Opinion in Cardiology</i> , 2009, 24, 351-357.	0.8	52
157	Fibrates in the treatment of cardiovascular risk and atherogenic dyslipidaemia. <i>Current Opinion in Cardiology</i> , 2009, 24, 372-379.	0.8	31
158	Future Challenges for Microsomal Transport Protein Inhibitors. <i>Current Vascular Pharmacology</i> , 2009, 7, 277-286.	0.8	43
159	Potential Options to Treat Hypertriglyceridaemia. <i>Current Drug Targets</i> , 2009, 10, 356-362.	1.0	6
160	The relationship between serum copper and ceruloplasmin in routine clinical practice. <i>International Journal of Clinical Practice</i> , 2008, 62, 485-487.	0.8	9
161	Non-ceruloplasmin-bound copper in routine clinical practice in different laboratories. <i>Journal of Trace Elements in Medicine and Biology</i> , 2008, 22, 50-53.	1.5	34
162	Multiple actions of high-density lipoprotein. <i>Current Opinion in Cardiology</i> , 2008, 23, 370-378.	0.8	180

#	ARTICLE	IF	CITATIONS
163	Lipoproteins: from A to B and maybe C-III. International Journal of Clinical Practice, 2008, 62, 674-676.	0.8	7
164	Enhanced LDL-C reduction: lower is better. Does it matter how?. International Journal of Clinical Practice, 2008, 62, 518-520.	0.8	9
165	Insulin resistance phenotypes and coronary artery disease in a native Pakistani cohort. International Journal of Clinical Practice, 2008, 62, 701-707.	0.8	3
166	A fishy business: omega-3 fatty acids and cardiovascular disease. International Journal of Clinical Practice, 2008, 62, 1142-1146.	0.8	15
167	Shielding the population from the metabolic syndrome? There is one born every minute. International Journal of Clinical Practice, 2008, 62, 1132-1134.	0.8	0
168	Surrogate markers, atherosclerosis and cardiovascular disease prevention. International Journal of Clinical Practice, 2008, 62, 981-987.	0.8	29
169	Muddy waters: more stormy SEAS for ezetimibe. International Journal of Clinical Practice, 2008, 62, 1470-1473.	0.8	16
170	±Methylacetyl-CoA racemase±fan ±an ±obscura™ metabolic enzyme takes centre stage. FEBS Journal, 2008, 275, 1089-1102.	2.2	98
171	The relationship between gonadotrophins, gonadal hormones and bone mass in men. Clinical Endocrinology, 2008, 68, 94-101.	1.2	16
172	Waist circumference, metabolic syndrome and coronary artery disease in a Pakistani cohort. International Journal of Cardiology, 2008, 128, 77-82.	0.8	8
173	Epidemiological Studies Are Meaningless without Proof of Long-Term Data Stability. American Journal of Medicine, 2008, 121, e7.	0.6	2
174	The 2007 Heart-UK Survey of Lipid Clinics and Clinical Practice in the UK. Atherosclerosis, 2008, 199, 234.	0.4	3
175	HIV lipodystrophy and its metabolic consequences: implications for clinical practice. Current Medical Research and Opinion, 2008, 24, 609-624.	0.9	36
176	Identifying patients with familial hypercholesterolaemia in primary care: an informatics-based approach in one primary care centre. Heart, 2008, 94, 754-758.	1.2	63
177	Colesevelam hydrochloride: a specifically engineered bile acid sequestrant. Future Lipidology, 2008, 3, 237-255.	0.5	15
178	Familial Combined Hyperlipidaemia: Under - Defined and Under - Diagnosed?. Current Vascular Pharmacology, 2008, 6, 13-22.	0.8	35
179	Review: Clinical aspects of the management of HIV lipodystrophy. British Journal of Diabetes and Vascular Disease, 2008, 8, 113-119.	0.6	4
180	Targeted versus global approaches to the management of hypercholesterolaemia. Perspectives in Public Health, 2008, 128, 248-254.	0.5	6

#	ARTICLE	IF	CITATIONS
181	New Approaches in the Diagnosis of Atherosclerosis and Treatment of Cardiovascular Disease. Recent Patents on Cardiovascular Drug Discovery, 2008, 3, 84-91.	1.5	9
182	Detection of small dense LDL-cholesterol: is it necessary to determine particle size?. Future Lipidology, 2008, 3, 23-25.	0.5	1
183	Familial hypercholesterolaemia: summary of NICE guidance. BMJ: British Medical Journal, 2008, 337, a1095-a1095.	2.4	203
184	The UK needs an Institute of Medicine. BMJ: British Medical Journal, 2008, 337, a1623-a1623.	2.4	2
185	Homocysteine and cardiovascular disease: a review of the evidence. Diabetes and Vascular Disease Research, 2007, 4, 143-149.	0.9	235
186	Asymmetric Dimethylarginine and Reduced Nitric Oxide Bioavailability in Young Black African Men. Hypertension, 2007, 49, 873-877.	1.3	63
187	How aggressively should cholesterol targets be pursued?. British Journal of Hospital Medicine (London, England: 2005), 2007, 68, 232-233.	0.2	0
188	Editorial [PCI and Stable Coronary Heart Disease - COURAGE to Change Our Minds?]. Current Vascular Pharmacology, 2007, 5, 173-174.	0.8	1
189	Dr Brian Gibberd (1931-2006): a pioneering clinician in Refsum's disease. Biochemical Society Transactions, 2007, 35, 862-864.	1.6	2
190	Peroxisomal disorders affecting phytanic acid β -oxidation: a review. Biochemical Society Transactions, 2007, 35, 881-886.	1.6	61
191	Proprotein convertase subtilisin/kexin type 9, its variants and regulation of low-density lipoprotein cholesterol. Current Opinion in Lipidology, 2007, 18, 227-229.	1.2	1
192	Shape of the Nations survey and attitudes to cardiometabolic risk. Current Medical Research and Opinion, 2007, 23, 25-28.	0.9	10
193	Differential effect of pioglitazone (PGZ) and rosiglitazone (RGZ) on postprandial glucose and lipid metabolism in patients with type 2 diabetes mellitus: a prospective, randomized crossover study. Diabetes/Metabolism Research and Reviews, 2007, 23, 392-399.	1.7	50
194	Percentage non-caeruloplasmin bound copper. Clinical Biochemistry, 2007, 40, 749-750.	0.8	14
195	Newer, lower, better? Lipid drugs and cardiovascular disease - the continuing story. International Journal of Clinical Practice, 2007, 61, 1064-1067.	0.8	5
196	Raising HDL-C: back to the future?. International Journal of Clinical Practice, 2007, 61, 1069-1071.	0.8	1
197	Targets - who needs them? Success with statin therapies. International Journal of Clinical Practice, 2007, 61, 1239-1242.	0.8	1
198	Primary and secondary prevention in obesity. International Journal of Clinical Practice, 2007, 61, 1431-1434.	0.8	2

#	ARTICLE	IF	CITATIONS
199	Intervening on HDL-C: Is it possible? Does it work?*. International Journal of Clinical Practice, 2007, 61, 1782-1786.	0.8	6
200	Quality as well as quantity? Beyond low-density lipoprotein-cholesterol - the role of particle size*. International Journal of Clinical Practice, 2007, 61, 1780-1782.	0.8	11
201	Lipid-Altering Therapies and the Progression of Atherosclerotic Disease. CardioVascular and Interventional Radiology, 2007, 30, 155-160.	0.9	8
202	Lipid-Altering Therapies and the Progression of Atherosclerotic Disease. CardioVascular and Interventional Radiology, 2007, 30, 155.	0.9	0
203	Limitations of non-ceruloplasmin-bound copper in routine clinical practice. Gut, 2007, 56, 154.	6.1	14
204	Spinning stars: ASTEROID's impact on atherosclerosis. Lancet, The, 2006, 367, 1655-1656.	6.3	2
205	Asymmetric dimethyl arginine levels correlate with cardiovascular risk factors in patients with erectile dysfunction. Atherosclerosis, 2006, 185, 421-425.	0.4	33
206	Fibrates after the FIELD study: some answers, more questions. Diabetes and Vascular Disease Research, 2006, 3, 166-171.	0.9	10
207	Cardiovascular Risk Factors Determine Erectile and Arterial Function Response to Sildenafil. American Journal of Hypertension, 2006, 19, 915-919.	1.0	32
208	Future approaches to reducing low-density lipoprotein cholesterol. Future Lipidology, 2006, 1, 463-476.	0.5	1
209	Diabetic dyslipidaemia: the triad. Country Review Ukraine, 2006, 8, F30-F33.	0.8	2
210	FIELDS of dreams, fields of tears: a perspective on the fibrate trials. International Journal of Clinical Practice, 2006, 60, 442-449.	0.8	57
211	Erectile dysfunction and statin treatment in high cardiovascular risk patients. International Journal of Clinical Practice, 2006, 60, 141-145.	0.8	80
212	Lipid lowering, statins and cancer. International Journal of Clinical Practice, 2006, 60, 1022-1024.	0.8	2
213	Low HDL-cholesterol: common and under-treated, but which drug to use?. International Journal of Clinical Practice, 2006, 60, 1149-1153.	0.8	12
214	Rimonabant: endocannabinoid inhibition for the metabolic syndrome. International Journal of Clinical Practice, 2006, 60, 1697-1706.	0.8	35
215	Statins and hypertension. Journal of Human Hypertension, 2006, 20, 554-556.	1.0	9
216	Mutational analysis in UK patients with a clinical diagnosis of familial hypercholesterolaemia: relationship with plasma lipid traits, heart disease risk and utility in relative tracing. Journal of Molecular Medicine, 2006, 84, 203-214.	1.7	61

#	ARTICLE	IF	CITATIONS
217	Plasma Lipid Profiles of Women With Intrahepatic Cholestasis of Pregnancy. <i>Obstetrics and Gynecology</i> , 2006, 107, 106-114.	1.2	61
218	Low-density lipoprotein apolipoprotein B100 turnover in hypopituitary patients with GH deficiency: a stable isotope study. <i>European Journal of Endocrinology</i> , 2006, 154, 459-466.	1.9	10
219	Copper:ceruloplasmin ratio. <i>Journal of Clinical Pathology</i> , 2006, 60, 441-442.	1.0	28
220	Adjusting copper concentrations for ceruloplasmin levels in routine clinical practice. <i>Journal of Clinical Pathology</i> , 2006, 59, 867-869.	1.0	21
221	Molecular mechanisms of atherosclerosis. <i>International Journal of Clinical Practice</i> , 2005, 59, 1120-1120.	0.8	0
222	Ezetimibe-induced hyperlipidaemia. <i>International Journal of Clinical Practice</i> , 2005, 59, 3-5.	0.8	12
223	Hypertriglyceridaemia and malignancy. <i>International Journal of Clinical Practice</i> , 2005, 59, 253-255.	0.8	3
224	Molecular genetics and phenotypic characteristics of MODY caused by hepatocyte nuclear factor 4 β mutations in a large European collection. <i>Diabetologia</i> , 2005, 48, 878-885.	2.9	203
225	The role of dyslipidaemia in coronary heart disease. <i>British Journal of Diabetes and Vascular Disease</i> , 2005, 5, S2-S6.	0.6	1
226	Metabolic syndrome and risk of coronary heart disease in a Pakistani cohort. <i>Heart</i> , 2005, 91, 1003-1007.	1.2	19
227	Letter Regarding Article by Gazzaruso et al, "Relationship Between Erectile Dysfunction and Silent Myocardial Ischemia in Apparently Uncomplicated Type 2 Diabetic Patients"; <i>Circulation</i> , 2005, 111, e18-9; author reply e18-9.	1.6	1
228	Very low plasma copper levels do not automatically imply severe copper deficiency. <i>Annals of Clinical Biochemistry</i> , 2005, 42, 405-405.	0.8	5
229	Lipemia Retinalis. <i>New England Journal of Medicine</i> , 2005, 353, 823-823.	13.9	10
230	Efficacy of ezetimibe in patients with statin-resistant and statin-intolerant familial hyperlipidaemias. <i>Current Medical Research and Opinion</i> , 2005, 21, 333-338.	0.9	40
231	Relationship between Serum Copper, Ceruloplasmin, and Non-Ceruloplasmin-Bound Copper in Routine Clinical Practice. <i>Clinical Chemistry</i> , 2005, 51, 1558-1559.	1.5	111
232	Cardiovascular risk assessment. <i>Lancet, The</i> , 2005, 365, 1305-1306.	6.3	3
233	Dyslipidaemia and cardiovascular risk in HIV infection. <i>Current Medical Research and Opinion</i> , 2005, 21, 1717-1725.	0.9	19
234	Impaired renal function and atherosclerosis in a Pakistani cohort. <i>Current Medical Research and Opinion</i> , 2005, 21, 1201-1207.	0.9	4

#	ARTICLE	IF	CITATIONS
235	The use of ezetimibe in achieving low density lipoprotein lowering goals in clinical practice: position statement of a United Kingdom consensus panel. <i>Current Medical Research and Opinion</i> , 2005, 21, 959-969.	0.9	68
236	A review of the lipid-related effects of fluvastatin. <i>Current Medical Research and Opinion</i> , 2005, 21, 231-243.	0.9	37
237	Have we forgotten the pivotal role of high-density lipoprotein cholesterol in atherosclerosis prevention?. <i>Current Medical Research and Opinion</i> , 2005, 21, 299-305.	0.9	23
238	Effects of Growth Hormone (GH) Replacement Therapy on Low-Density Lipoprotein Apolipoprotein B100 Kinetics in Adult Patients with GH Deficiency: A Stable Isotope Study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2004, 89, 1801-1807.	1.8	24
239	Polymorphisms in the P450 c17 (17-Hydroxylase/17,20-Lyase) and P450 c19 (Aromatase) Genes: Association with Serum Sex Steroid Concentrations and Bone Mineral Density in Postmenopausal Women. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2004, 89, 344-351.	1.8	107
240	Does activity in research correlate with visibility?. <i>Journal of Clinical Pathology</i> , 2004, 57, 426-427.	1.0	6
241	Screening for cardiovascular disease. <i>European Heart Journal</i> , 2004, 25, 996.	1.0	1
242	Smell testing: an additional tool for identification of adult Refsum's disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2004, 75, 1334-1336.	0.9	26
243	The casino of life. <i>Journal of Clinical Pathology</i> , 2004, 57, 243-244.	1.0	1
244	Chemical pathology and the new contract for GPs. <i>Journal of Clinical Pathology</i> , 2004, 57, 1022-1024.	1.0	8
245	Biological Variation in HbA1c Predicts Risk of Retinopathy and Nephropathy in Type 1 Diabetes: Response to McCarter et al.. <i>Diabetes Care</i> , 2004, 27, 2569-2569.	4.3	65
246	Waist-hip ratio and low HDL predict the risk of coronary artery disease in Pakistanis. <i>Current Medical Research and Opinion</i> , 2004, 20, 55-62.	0.9	44
247	Effect of moxonidine on lipid subfractions in patients with hypertension. <i>International Journal of Clinical Practice</i> , 2004, 58, 465-468.	0.8	19
248	Cardiovascular disease in renal allograft recipients is associated with elevated sialic acid or markers of inflammation. <i>Clinical Transplantation</i> , 2004, 18, 201-204.	0.8	26
249	Lipid-altering agents: the future. <i>International Journal of Clinical Practice</i> , 2004, 58, 1063-1072.	0.8	22
250	Raising high-density lipoprotein. <i>International Journal of Clinical Practice</i> , 2004, 58, 817-819.	0.8	0
251	Psychological impact of genetic testing for familial hypercholesterolemia within a previously aware population: A randomized controlled trial. <i>American Journal of Medical Genetics Part A</i> , 2004, 128A, 285-293.	2.4	172
252	Lipid-lowering therapies in development. <i>Expert Opinion on Investigational Drugs</i> , 2004, 13, 1405-1418.	1.9	6

#	ARTICLE	IF	CITATIONS
253	Concordance evaluation of coronary risk scores: implications for cardiovascular risk screening. <i>Current Medical Research and Opinion</i> , 2004, 20, 811-818.	0.9	24
254	Clinical significance of oxidation from phytol to phytanic acid in man. <i>Molecular Genetics and Metabolism</i> , 2004, 83, 347.	0.5	6
255	Cost utility of prenatal diagnosis. <i>Lancet, The</i> , 2004, 363, 1165.	6.3	1
256	Genetics and molecular biology: Genetic epidemiology. <i>Current Opinion in Lipidology</i> , 2004, 15, 699-701.	1.2	0
257	Cardiovascular risk factors and endothelial dysfunction. <i>Clinical Science</i> , 2004, 107, 609-615.	1.8	31
258	Role of Phytanoyl-CoA 2-Hydroxylase in Phytanic Acid Metabolism. <i>Advances in Experimental Medicine and Biology</i> , 2004, 544, 303-304.	0.8	1
259	Use of coronary calcification scores to predict coronary heart disease. <i>JAMA - Journal of the American Medical Association</i> , 2004, 291, 1831; author reply 1832-3.	3.8	0
260	Relation of erectile dysfunction to angiographic coronary artery disease. <i>American Journal of Cardiology</i> , 2003, 91, 230-231.	0.7	208
261	The lipid and non-lipid effects of statins. , 2003, 99, 95-112.		217
262	Statin-fibrate combination therapy for hyperlipidaemia: a review. <i>Current Medical Research and Opinion</i> , 2003, 19, 155-168.	0.9	156
263	More on PROSPER. <i>Lancet, The</i> , 2003, 361, 1135-1136.	6.3	10
264	The chemical biology of branched-chain lipid metabolism. <i>Progress in Lipid Research</i> , 2003, 42, 359-376.	5.3	71
265	Imidazole derivatives as cholesterol-lowering agents. <i>International Journal of Cardiology</i> , 2003, 90, 145-146.	0.8	3
266	Cerivastatin monotherapy-induced muscle weakness, rhabdomyolysis and acute renal failure. <i>International Journal of Cardiology</i> , 2003, 91, 107-109.	0.8	9
267	Identification of PEX7 as the Second Gene Involved in Refsum Disease. <i>American Journal of Human Genetics</i> , 2003, 72, 471-477.	2.6	151
268	Ezetimibe: profile report. <i>Drugs and Therapy Perspectives</i> , 2003, 19, 5-7.	0.3	0
269	Issues to consider when attempting to achieve the American Diabetes Association clinical quality requirement for haemoglobin A1c. <i>Current Medical Research and Opinion</i> , 2003, 19, 719-723.	0.9	22
270	Metabolism of phytanic acid and 3-methyl-adipic acid excretion in patients with adult Refsum disease. <i>Journal of Lipid Research</i> , 2003, 44, 1481-1488.	2.0	36

#	ARTICLE	IF	CITATIONS
271	New lipid-lowering agents. <i>Expert Opinion on Emerging Drugs</i> , 2003, 8, 365-376.	1.0	12
272	Simple Sequence-specific-Primer-PCR Method To Identify the Three Main Apolipoprotein E Haplotypes. <i>Clinical Chemistry</i> , 2003, 49, 1945-1948.	1.5	30
273	Accuracy of Cardiovascular Risk Estimation. <i>Clinical Chemistry</i> , 2003, 49, 706-707.	1.5	0
274	Ezetimibe. <i>American Journal of Cardiovascular Drugs</i> , 2003, 3, 77-78.	1.0	1
275	Accuracy of Cardiovascular Risk Estimation in Patients without Diabetes. <i>Clinical Science</i> , 2003, 104, 16P-16P.	0.0	3
276	Statin therapy in people with diabetes and high-risk patients. <i>British Journal of Hospital Medicine</i> , 2003, 64, 16-19.	0.3	2
277	Identification of PEX7 as the Second Gene Involved in Refsum Disease. <i>Advances in Experimental Medicine and Biology</i> , 2003, 544, 69-70.	0.8	13
278	Erectile dysfunction: cardiovascular risk and the role of the cardiologist. <i>International Journal of Clinical Practice</i> , 2003, 57, 96-9.	0.8	43
279	Ezetimibe: a new addition to lipid-lowering therapy. <i>International Journal of Clinical Practice</i> , 2003, 57, 653-5.	0.8	4
280	Raised plasma total sialic acid levels are markers of cardiovascular disease in renal dialysis patients. <i>Journal of Nephrology</i> , 2003, 16, 540-5.	0.9	20
281	Hypertriglyceridaemia and NK cell lymphoma. <i>International Journal of Clinical Practice</i> , 2003, 57, 921-2.	0.8	2
282	Accuracy of Cardiovascular Risk Estimation for Primary Prevention in Patients Without Diabetes. <i>European Journal of Cardiovascular Prevention and Rehabilitation</i> , 2002, 9, 183-190.	3.1	33
283	Title is missing!. <i>European Journal of Cardiovascular Prevention and Rehabilitation</i> , 2002, 9, 183-190.	1.5	65
284	Beyond LDL-C – The Importance of Raising HDL-C. <i>Current Medical Research and Opinion</i> , 2002, 18, 36-44.	0.9	42
285	Stroke in systemic lupus erythematosus. <i>Expert Review of Neurotherapeutics</i> , 2002, 2, 385-390.	1.4	0
286	The GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) Study. <i>Current Medical Research and Opinion</i> , 2002, 18, 215-219.	0.9	38
287	The apolipoprotein E2 allele modulates activity and maximal velocity of the sodium-lithium countertransporter1. <i>American Journal of Hypertension</i> , 2002, 15, 633-637.	1.0	10
288	Dose-response effects of atorvastatin and simvastatin on high-density lipoprotein cholesterol in hypercholesterolaemic patients: a review of five comparative studies. <i>International Journal of Cardiology</i> , 2002, 84, 53-57.	0.8	46

#	ARTICLE	IF	CITATIONS
289	Effect of IGF-I therapy on VLDL apolipoprotein B100 metabolism in type 1 diabetes mellitus. American Journal of Physiology - Endocrinology and Metabolism, 2002, 282, E1154-E1162.	1.8	12
290	Usefulness of Orlistat in the treatment of severe hypertriglyceridemia. American Journal of Cardiology, 2002, 89, 229-231.	0.7	30
291	Refsum's disease: a peroxisomal disorder affecting phytanic acid alpha-oxidation. Journal of Neurochemistry, 2002, 80, 727-735.	2.1	182
292	Utilization of Sterol Carrier Protein-2 by Phytanoyl-CoA 2-Hydroxylase in the Peroxisomal α Oxidation of Phytanic Acid. Chemistry and Biology, 2002, 9, 597-605.	6.2	51
293	Lipid lowering: another method of reducing blood pressure?. Journal of Human Hypertension, 2002, 16, 753-760.	1.0	41
294	The Uptake of Lipoprotein-Borne Phylloquinone (Vitamin K1) by Osteoblasts and Osteoblast-Like Cells: Role of Heparan Sulfate Proteoglycans and Apolipoprotein E. Journal of Bone and Mineral Research, 2002, 17, 426-433.	3.1	60
295	Total research productivity in a pathology discipline. Journal of Clinical Pathology, 2002, 55, 495-498.	1.0	8
296	Relation between sodium-lithium countertransport and hypertriglyceridemia in type V hyperlipidemia. American Journal of Hypertension, 2001, 14, 32-37.	1.0	7
297	Statins and fractures. Lancet, The, 2001, 357, 1887.	6.3	3
298	Measurement of atherosclerosis progression. Lancet, The, 2001, 358, 329-330.	6.3	2
299	Drug Treatment of Combined Hyperlipidemia. American Journal of Cardiovascular Drugs, 2001, 1, 327-336.	1.0	23
300	Atorvastatin. Expert Opinion on Pharmacotherapy, 2001, 2, 819-830.	0.9	22
301	Chemical co-substrate rescue™ of phytanoyl-CoA 2-hydroxylase mutants causing Refsum™s Disease. Chemical Communications, 2001, , 972-973.	2.2	27
302	Normal VLDL metabolism despite altered lipoprotein composition in type 1 diabetes mellitus. Clinical Endocrinology, 2001, 55, 777-787.	1.2	12
303	Vascular and Blood Pressure Effects of Folic Acid in Older Patients with Cardiovascular Disease. Journal of the American Geriatrics Society, 2001, 49, 1003-1004.	1.3	15
304	Studies on phytanoyl-CoA 2-hydroxylase and synthesis of phytanoyl-Coenzyme A. Bioorganic and Medicinal Chemistry Letters, 2001, 11, 2545-2548.	1.0	23
305	Very low-density lipoprotein apolipoprotein B-100 turnover in glycogen storage disease type Ia (von Tj ETQq1 1 0.784314 rgBT /Over	1.7	7
306	Erythrocyte sodium-lithium countertransport in African American women. Journal of Human Hypertension, 2001, 15, 505-506.	1.0	2

#	ARTICLE	IF	CITATIONS
307	Fibrinogen response with simvastatin versus atorvastatin in familial hypercholesterolemia. American Journal of Cardiology, 2001, 87, 338-340.	0.7	13
308	Time to look beyond just lowering the serum concentration of low density lipoprotein - high density lipoprotein levels are also important. Perspectives in Public Health, 2001, 121, 98-101.	0.5	2
309	Atorvastatin for Acute Coronary Syndromes. JAMA - Journal of the American Medical Association, 2001, 286, 532.	3.8	7
310	Structure-function analysis of phytanoyl-CoA 2-hydroxylase mutations causing Refsum's disease. Human Molecular Genetics, 2001, 10, 1971-1982.	1.4	64
311	Is a mechanical or a metabolic approach superior in the treatment of coronary disease? Results of the atorvastatin versus revascularization (AVERT) trial. European Heart Journal, 2001, 22, 972.	1.0	8
312	Lipid-lowering drugs in lupus: an unexplored therapeutic intervention. Lupus, 2001, 10, 233-236.	0.8	3
313	Synthetic Statins: More Data on Newer Lipid-lowering Agents. Current Medical Research and Opinion, 2001, 17, 74-77.	0.9	9
314	Comparison of therapy with simvastatin 80 mg and 120 mg in patients with familial hypercholesterolaemia. International Journal of Clinical Practice, 2001, 55, 673-5.	0.8	5
315	A Comparison of Algorithms for Initiation of Lipid Lowering Therapy in Primary Prevention of Coronary Heart Disease. European Journal of Cardiovascular Prevention and Rehabilitation, 2000, 7, 63-71.	3.1	26
316	Differing Relationships of Methylene Tetrahydrofolate Reductase Genotypes with Cardiovascular Risk in Familial and Polygenic Hypercholesterolaemia. European Journal of Cardiovascular Prevention and Rehabilitation, 2000, 7, 431-434.	3.1	0
317	Attaining United States and European Guideline LDL-C Levels with Simvastatin in Patients with Coronary Heart Disease (the GOALLS Study). Current Medical Research and Opinion, 2000, 16, 205-207.	0.9	3
318	Identification of genetic heterogeneity in Refsum's disease. European Journal of Human Genetics, 2000, 8, 649-651.	1.4	41
319	A randomised placebo controlled trial of the effects of tibolone on blood pressure and lipids in hypertensive women. Journal of Human Hypertension, 2000, 14, 99-104.	1.0	42
320	Effects of lipids in patients with familial hypercholesterolaemia on the kinetics of the sodium-lithium countertransporter. Journal of Human Hypertension, 2000, 14, 561-565.	1.0	1
321	High-density lipoprotein cholesterol and triglyceride response with simvastatin versus atorvastatin in familial hypercholesterolemia. American Journal of Cardiology, 2000, 86, 547-549.	0.7	25
322	Classification of acute MI. European Heart Journal, 2000, 21, 857-858.	1.0	0
323	HDL-cholesterol and the Treatment of Coronary Heart Disease: Contrasting Effects of Atorvastatin and Simvastatin. Current Medical Research and Opinion, 2000, 16, 139-146.	0.9	57
324	Natural Statins and Stroke. Circulation, 2000, 101, E45.	1.6	5

#	ARTICLE	IF	CITATIONS
325	Renin-Angiotensin System Polymorphisms and Coronary Events in Familial Hypercholesterolemia. Hypertension, 2000, 36, 808-812.	1.3	31
326	Are drugs interchangeable?. Lancet, The, 2000, 355, 317.	6.3	3
327	Effects of statins. Lancet, The, 2000, 356, 1195.	6.3	4
328	Coronary heart disease in Indian Asians. Lancet, The, 2000, 355, 1727-1728.	6.3	3
329	Lipids, cardiovascular disease and atherosclerosis in systemic lupus erythematosus. Lupus, 2000, 9, 194-201.	0.8	37
330	Correspondence. Atherosclerosis, 2000, 148, 204.	0.4	23
331	Correspondence. Atherosclerosis, 2000, 149, 221-222.	0.4	5
332	National service framework's financial implications are huge. BMJ: British Medical Journal, 2000, 321, 705-705.	2.4	1
333	Cost effectiveness of statins. British Heart Journal, 2000, 83, 713a-713.	2.2	0
334	National service framework's financial implications are huge. BMJ: British Medical Journal, 2000, 321, 705.	2.4	0
335	HDL-cholesterol and the treatment of coronary heart disease: contrasting effects of atorvastatin and simvastatin. Current Medical Research and Opinion, 2000, 16, 139-46.	0.9	9
336	Effects of Growth Hormone (GH) Replacement Therapy on Very Low Density Lipoprotein Apolipoprotein B100 Kinetics in Patients with Adult GH Deficiency: A Stable Isotope Study1. Journal of Clinical Endocrinology and Metabolism, 1999, 84, 307-316.	1.8	48
337	Urinary retinol-binding protein (RBP) excretion and erythrocyte sodium-lithium countertransport (SLC) activity in a cohort of healthy normotensive subjects. Journal of Human Hypertension, 1999, 13, 871-873.	1.0	0
338	Transport of phytanic acid on lipoproteins in Refsum disease. Journal of Inherited Metabolic Disease, 1999, 22, 29-36.	1.7	17
339	Cholestatic liver dysfunction. Lancet, The, 1999, 354, 954.	6.3	11
340	Thrombotic vascular events after change of statin. Lancet, The, 1999, 353, 845.	6.3	9
341	Atorvastatin compared with simvastatin-based therapies in the management of severe familial hyperlipidaemias. QJM - Monthly Journal of the Association of Physicians, 1999, 92, 387-394.	0.2	52
342	The role of lipid lowering in transplantation. International Journal of Clinical Practice, 1999, 53, 54-9.	0.8	14

#	ARTICLE	IF	CITATIONS
343	Comparison of therapy with simvastatin 80 mg and atorvastatin 80 mg in patients with familial hypercholesterolaemia. <i>International Journal of Clinical Practice</i> , 1999, 53, 609-11.	0.8	32
344	Influence of plasma phytanic acid levels in Refsum's disease on the behaviour of the erythrocyte membrane sodium-lithium countertransporter. <i>European Journal of Clinical Investigation</i> , 1998, 28, 334-338.	1.7	2
345	Effect of atorvastatin on plasma fibrinogen. <i>Lancet, The</i> , 1998, 351, 569-570.	6.3	96
346	Statins and fibrinogen. <i>Lancet, The</i> , 1998, 351, 1431-1432.	6.3	2
347	Lipid lowering therapy in patients with HIV infection. <i>Lancet, The</i> , 1998, 352, 1782.	6.3	22
348	Laboratory Investigations by DNA Amplification: From Research to Practice. <i>Annals of Clinical Biochemistry</i> , 1998, 35, 5-11.	0.8	4
349	High-dose atorvastatin therapy in severe heterozygous familial hypercholesterolaemia. <i>QJM - Monthly Journal of the Association of Physicians</i> , 1998, 91, 291-294.	0.2	19
350	People at risk of coronary heart disease should not be denied treatment with effective drugs for purely financial reasons. <i>BMJ: British Medical Journal</i> , 1998, 317, 80-80.	2.4	1
351	Profound hyponatraemia following an idiosyncratic reaction to diuretics. <i>International Journal of Clinical Practice</i> , 1998, 52, 278-9.	0.8	4
352	Fenofibrate plus simvastatin therapy versus simvastatin plus cholestyramine therapy for familial hypercholesterolaemia. <i>QJM - Monthly Journal of the Association of Physicians</i> , 1997, 90, 631-634.	0.2	23
353	Hyperlipidaemia in Association with Benign Paraproteinaemia. <i>Annals of Clinical Biochemistry</i> , 1997, 34, 697-699.	0.8	3
354	Preserved Endothelial Function in Patients With Severe Hypertriglyceridemia and Low Functional Lipoprotein Lipase Activity. <i>Journal of the American College of Cardiology</i> , 1997, 29, 964-968.	1.2	86
355	Ambiguities in angiotensin-converting enzyme allele genotyping; a comparison of three methods. <i>Journal of Human Hypertension</i> , 1997, 11, 467-467.	1.0	0
356	Diagnosis and management of hyperlipidaemia. <i>International Journal of Clinical Practice</i> , 1997, 51, 378-83.	0.8	1
357	Sheffield risk and treatment table for primary prevention of coronary heart disease. <i>Lancet, The</i> , 1996, 348, 1039-1040.	6.3	4
358	Familial hyperchylomicronaemia. <i>Lancet, The</i> , 1996, 348, 1524.	6.3	10
359	Patients with Recurrent Renal Stones Have a Physico-Chemically Altered Urinary Tamm-Horsfall Glycoprotein Profile. <i>Annals of Clinical Biochemistry</i> , 1996, 33, 540-544.	0.8	9
360	Full treatment of the costs and benefits is needed. <i>BMJ: British Medical Journal</i> , 1996, 313, 1143-1143.	2.4	0

#	ARTICLE	IF	CITATIONS
361	Sheffield risk and treatment table for cholesterol lowering in prevention of coronary heart disease. <i>Lancet, The</i> , 1996, 347, 466-7; author reply 468-9.	6.3	1
362	Health promotion in general practice. <i>BMJ: British Medical Journal</i> , 1995, 310, 532-533.	2.4	1
363	Strategies for reducing coronary risk factors in primary care. <i>BMJ: British Medical Journal</i> , 1995, 311, 263-263.	2.4	0
364	Association of angiotensin converting enzyme DD genotype with hypertension in diabetes. <i>Journal of Human Hypertension</i> , 1995, 9, 671-3.	1.0	9
365	Maternal serum free beta hCG screening: Results of studies including 480 cases of Down syndrome—problems with this approach. <i>Prenatal Diagnosis</i> , 1994, 14, 1093-1093.	1.1	1
366	Screening for secondary causes of hyperlipidaemia in general practice. <i>BMJ: British Medical Journal</i> , 1994, 309, 1373-1375.	2.4	2
367	Drug treatment of hypercholesterolaemia: Establish diagnosis before treatment. <i>BMJ: British Medical Journal</i> , 1994, 308, 56-56.	2.4	1
368	Methodological discrepancies are not important. <i>BMJ: British Medical Journal</i> , 1994, 309, 1511-1511.	2.4	0
369	Copper-64 metabolism in two patients with non-Wilsonian movement disorders and copper deficiency. <i>Journal of the Neurological Sciences</i> , 1993, 119, 85-90.	0.3	5
370	The Tissue Distribution of α -Subunit Genes of the Voltage-Gated Calcium Channel in Rodent Tissues and NG108-15 Cells. <i>Annals of the New York Academy of Sciences</i> , 1993, 681, 422-424.	1.8	1
371	Tissue-Specific Expression of Putative Domains of the Mouse Neuronal Alpha-2 and Delta Genes of the Voltage-Gated Calcium Channel in Rodent Tissues. <i>Annals of the New York Academy of Sciences</i> , 1993, 707, 472-475.	1.8	0
372	Hairy leukaemic cell influx into the cerebrospinal fluid secondary to encephalomyelitis. <i>Postgraduate Medical Journal</i> , 1993, 69, 651-653.	0.9	2
373	Molecular Biology Techniques. <i>Annals of Clinical Biochemistry</i> , 1993, 30, 332-333.	0.8	0
374	Paget's disease of bone.. <i>BMJ: British Medical Journal</i> , 1993, 306, 333-333.	2.4	0
375	The Hematological and Electrophysiological Effects of Cobalamin. <i>Annals of the New York Academy of Sciences</i> , 1992, 669, 345-348.	1.8	5
376	Cerebral neoplastic angioendotheliosis complicated by hypercalcaemia.. <i>Postgraduate Medical Journal</i> , 1991, 67, 571-573.	0.9	0
377	Immunocytological diagnosis of primary cerebral non-Hodgkin's lymphoma.. <i>Journal of Clinical Pathology</i> , 1991, 44, 251-253.	1.0	14
378	Effect of haemolysate preparation on measurement of red cell folate by a radioisotopic method.. <i>Journal of Clinical Pathology</i> , 1990, 43, 160-162.	1.0	10

#	ARTICLE	IF	CITATIONS
379	Autoimmunity: a risk factor for allosensitization to blood products?. BMJ: British Medical Journal, 1989, 298, 963-963.	2.4	0
380	Transient nephrotic syndrome after anaesthesia resulting from a familial cryofibrinogen precipitating at 35 degrees C.. Journal of Medical Genetics, 1989, 26, 631-636.	1.5	9
381	Autoimmunity: a risk factor for allosensitisation to blood products?. BMJ: British Medical Journal, 1989, 298, 95-96.	2.4	0
382	SCREENING FOR INHERITED METABOLIC DISEASES IN ADULTS WITH NEUROLOGICAL DISEASE. Lancet, The, 1988, 331, 1101.	6.3	0
383	Lipid-Lowering in the Elderly Patient. , 0, , 101-110.		0